Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NetraMark Holdings Inc C.AIAI

Alternate Symbol(s):  AINMF

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.


CSE:AIAI - Post by User

Post by StockHawk1on Feb 16, 2022 3:27pm
137 Views
Post# 34435059

Nutra AI to be used in drug ID study

Nutra AI to be used in drug ID study

Last week Nurosene Health Inc. ( $MEND.C $MNNDF) announced that it was selected by Mitacs Inc, alongside The University of Toronto to help conduct research into mitochondrial genetics in neuropsychiatric and neurodegenerative diseases.


In this research $MEND's proprietary AI tech, NutraAI will be used to fast-track the identification of novel and commercially viable drug candidates for neuropsychiatric and neurodegenerative diseases.


$MEND was chosen because of positive results from earlier research completed at the UoT using its NetraAI artificial intelligence technology.


Right now $MEND is trading stable at @ $0.68, MC is $22.965M


https://ca.finance.yahoo.com/news/nurosene-announces-research-partnership-designed-130000105.html

 
<< Previous
Bullboard Posts
Next >>